Based in McLean, Virginia, Freddie Mac was established by Congress in 1970 to provide liquidity, stability and affordability to the nation’s residential mortgage markets. Freddie Mac supports communities across the nation by providing mortgage capital to lenders.

Freddie Mac has been under conservatorship, with the Federal Housing Finance Agency (FHFA) acting as conservator, since September 6, 2008.

In its latest monthly summary report, Freddie Mac reported that its total mortgage portfolio decreased at an annualized rate of 10.0% in December. Single-family refinance-loan purchase and guarantee volume was $23.3 billion in December, representing 76% of total mortgage portfolio purchases and issuances. The company’s total number of loan modifications were 5,591 for the month and 109,174 for the twelve months ended December 31, 2011.

The aggregate unpaid principal balance (UPB) of its mortgage-related investments portfolio decreased by about $10.0 billion in December.  Meanwhile, Freddie Mac mortgage-related securities and other guarantee commitments decreased at an annualized rate of 14.8% in December.

The company’s single-family seriously delinquent rate increased from 3.57% in November to 3.58% in December, while multifamily delinquency rate decreased from 0.28% in November to 0.22% in December.

The measure of the company’s exposure to changes in portfolio market value (PMVS-L) averaged $302 million in December.

Freddie Mac on Thursday released the results of its Primary Mortgage Market Survey (PMMS), showing most average mortgage rates inching higher on January’s positive employment data. The 30-year fixed remained unchanged and at its all-time record low. One year ago at this time, the 30-year fixed averaged 5.05%.

Also this week, the company announced its sixth offering of Structured Pass-Through Certificates (K Certificates) backed exclusively by multifamily mortgages with a 7-year term.  The company expects to offer approximately $1.0 billion in K Certificates (K-706 Certificates), which are expected to price the week of February 6, 2012, and settle on or about February 28, 2012.  This is Freddie Mac’s second K Certificate offering this year.

FMCC shares added $0.03, or 9.58%, to close trade at $0.33.  The stock has so far reached a 52-week high of $0.80, its 52-week low being $0.18. Market capitalization currently stands at 1.05 billion and it has 3.22 billion outstanding shares.

• This newsletter has been helping traders make a killing on FMCC. Click here for a 15% discount offer.
• See today’s top stock picks and market analysis
• Need fast service and cheap rates from a broker? Buy stock online at my favorite brokerage
• Want more? Check out the message board buzz for FMCC
• See what newsletters are recommending this stock pick
• Get breaking news alerts on these stocks: http://thestockmarketwatch.com/

Related Articles

1. Small-Cap Stock Spotlight: LiveDeal Inc. (LIVE) Trades Higher after CEO Sacking
2. OTC Stock Spotlight: SNAP Interactive Inc. (STVI)
3. Small-Cap Stock Spotlight: Columbia Laboratories Inc. (CBRX)

North Springs yesterday announced the receipt of additional geochemical results, including silver values from the initial sampling program conducted during phase one exploration at the Imperial Gold Silver Property.

NSRS shares saw an interesting spike in late January after the company said it has commenced phase one exploration at the said property in Esmeralda County Nevada, located about 150 miles northwest of Las Vegas in the Railroad Springs Mining District.

Commenting on the latest news, North Springs President Harry Lappa said all of the underground samples from the initial phase one exploration program tested positive for silver, another important confirmation that the Company’s assessment of the potential at Imperial is correct.  Lappa added that the consistency, grade, and potential scale of the gold and silver mineralization encountered at the old Imperial Mine site and Resources Target area are all very bullish indicators for the project.

As previously reported, the Imperial Property consists of 24 unpatented mineral claims covering about 480 acres and includes the historic workings of the high-grade Imperial Mine. Previous exploration has identified four high-priority target areas at the Imperial Property; Imperial Fault Target, Jasperoid Breccia Target, IP Target, and Resource Target. Geochemical and environmental studies are expected to be followed by a reverse-circulation drilling program intended to test previously identified mineralized zones and potentially increase the 50 K ounce gold resource estimate made by previous operators.

North Springs expects phase one exploration expenditures at the Imperial Property to surpass $250 K this year.

As stated by Lappa, the Imperial Property is a vital component in the company’s exploration portfolio because it has many of the key characteristics we look for in a potential mining project, including close proximity to historic production, clearly defined exploration targets, and a strong possibility for additional gold discoveries.

This, along with the North Springs Property in Nevada and the Goldstar Property in Arizona, make three currently active exploration programs underway for the company,” Lappa said.

Shares of NSRS have gained 19.2% in the last five days; 104.6% in the last month; and 9,600.0% in the six months to date.

• This newsletter has been helping traders make a killing on NSRS. Click here for a 15% discount offer.
• See today’s top stock picks and market analysis
• Need fast service and cheap rates from a broker? Buy stock online at my favorite brokerage
• Want more? Check out the message board buzz for NSRS
• See what newsletters are recommending this stock pick
• Get breaking news alerts on these stocks: http://thestockmarketwatch.com/

Related Articles

1. Penny-Cap Stock on Watch: North Spring Resources Corp. (NSRS)
2. Stock Alert for North Springs Resources Corp. (NSRS)
3. Stock Alert for North Springs Resources Corp. (NSRS)

“We are excited by the new resources that our partnership is going to bring to the development of TH-302 and the expertise in clinical development and commercialization that Merck will contribute to this program,” Barry Selick, president and CEO of Threshold, commented in the release.  “This collaboration provides Threshold a strong and committed partner with a shared vision for TH-302.”

Threshold, based out of Red Wood City, CA, will have primary responsibility for development of TH-302 in the soft tissue sarcoma indication in the United States. It and Merck will jointly develop TH-302 in all other cancer indications being pursued, with Merck KGaA paying 70% of worldwide development costs for the drug.

Merck KGaA will commercialize TH-302 in the United States, with Threshold receiving a tiered, double-digit royalty on sales.  Threshold, however, retains the option to co-promote and co-commercialize the drug, allowing the company to participate in up to 50% of the profits in the United States based on certain revenue tiers.

Outside of the U.S., Merck KGaA will be solely responsible for the commercialization of the drug, with Threshold receiving a tiered, double-digit royalty on sales in these territories.

In total, Threshold could receive up to $525 million in milestone payments, comprised of $280 million in regulatory and development milestones and $245 million in sales-based milestones.

TH-302 is a hypoxia-targeted drug that is thought to be activated under tumor hypoxic conditions, a hallmark for many cancer indications.To date, the drug has been investigated in over 550 patients in Phase I/II clinical trials in a broad spectrum of tumor types, both as a monotherapy and in combination with chemotherapy treatments and other targeted cancer drugs.

Shares of THLD added $0.39, or 13.04%, to close Monday’s trade at $3.38.  Over 19.72 million shares exchanged hands during the session, topping the 10-day average of 1.81 million.

• This newsletter has been helping traders make a killing on THLD. Click here for a 15% discount offer.
• See today’s top stock picks and market analysis
• Need fast service and cheap rates from a broker? Buy stock online at my favorite brokerage
• Want more? Check out the message board buzz for THLD
• See what newsletters are recommending this stock pick
• Get breaking news alerts on these stocks: http://thestockmarketwatch.com/

Related Articles

1. Small-Cap Stock Spotlight: Threshold Pharmaceuticals Inc. (THLD) Spikes on Multi-Million Cancer Drug Pact with Merck KGaA
2. Small-Cap Stock Spotlight: Tengion Inc. (TNGN)
3. Small-Cap Stock Spotlight: New Patent Announcement Drives Marshall Edwards (MSHL) Shares Up 11%

TH-302 is a hypoxia-targeted drug that is thought to be activated under tumor hypoxic conditions, a hallmark for many cancer indications. The drug is currently in a global Phase III clinical trial in patients with soft tissue sarcoma, a randomized Phase II trial in patients with advanced pancreatic cancer from which top-line results are expected in this month, as well as additional clinical studies in other solid tumors and hematological malignancies.

Under the deal, Darmstadt, Germany-based Merck KGaA will pay Threshold $25 million immediately. In addition, Threshold could receive up to $35 million in development milestones this year and $20 million with positive results from its randomized Phase II trial in pancreatic cancer.

Threshold could receive up to $525 million in total milestone payments, comprised of $280 million in regulatory and development milestones and $245 million in sales-based milestones.

Threshold will have primary responsibility for development of TH-302 in the soft tissue sarcoma indication in the United States. The company and Merck will jointly develop TH-302 in all other cancer indications being pursued, with Merck paying 70% of worldwide development costs for the drug.

The deal provides for Merck KGaA to commercialize TH-302 in the United States, with Threshold receiving a tiered, double-digit royalty on sales.  Threshold, however, retains the option to co-promote and co-commercialize the drug, allowing the company to participate in up to 50% of the profits in the United States based on certain revenue tiers.

Merck KGaA will be solely responsible for the commercialization of TH-302 outside of the U.S., with Threshold receiving a tiered, double-digit royalty on sales in these territories.

“We are excited by the new resources that our partnership is going to bring to the development of TH-302 and the expertise in clinical development and commercialization that Merck will contribute to this program,” Barry Selick, president and CEO of Threshold, commented in the release.  “This collaboration provides Threshold a strong and committed partner with a shared vision for TH-302.”

Shares of THLD added $1.70, or 131.8%, to close Friday’s trade at $2.99.  Shares have gained 119.9% in the last five days; 116.7% in the last month; and 69.9% year-to-date.

• This newsletter has been helping traders make a killing on THLD. Click here for a 15% discount offer.
• See today’s top stock picks and market analysis
• Need fast service and cheap rates from a broker? Buy stock online at my favorite brokerage
• Want more? Check out the message board buzz for THLD
• See what newsletters are recommending this stock pick
• Get breaking news alerts on these stocks: http://thestockmarketwatch.com/

Related Articles

1. Small-Cap Stock Spotlight: Threshold Pharmaceuticals Inc. (THLD) Sets a New 52-Week High
2. Small-Cap Stock Spotlight: Tengion Inc. (TNGN)
3. Small-Cap Stock Spotlight: New Patent Announcement Drives Marshall Edwards (MSHL) Shares Up 11%

Vringo, based out of New York, New York, provides software platforms for mobile social and video applications. With its award-winning video ringtone application and other mobile software platforms – including Facetones, Video Remix and Fan Loyalty – Vringo transforms the basic act of making and receiving mobile phone calls into a highly visual, social experience.

Late last month, the company unveiled a new version of Facetones customized for the latest mobile devices released by mobile phone giant Nokia. The Facetones app is integrated with Facebook and generates an automatic, visually exciting slideshow of photos displaying one’s friend’s face and other social content each time one communicates with that friend using a mobile device.

With the latest version of Facetones, the application is now fully optimized for Nokia’s Symbian^3 operating system, including its latest Anna and Belle extensions, which were released in the second half of 2011, Vringo said in a statement.

“The ongoing innovation that Vringo brings to the latest Symbian handsets further solidifies our commitment to delivering best-of-breed video and social experiences to Nokia users around the world, especially in the Middle East, Asia, and Europe,” commented Vringo CEO Jon Medved.

According to Vringo president Andrew Perlman, Vringo has developed Symbian versions of its Video Ringtone, Fan Loyalty, and Facetones apps for S40, S60, and Symbian^3 device since 2007, potentially reaching over 1 million Nokia users and enhancing many calls along the way.

Vringo reported revenue of $182,000 for third quarter ended September 30, 2011, an increase of 237% from third quarter of 2011. The Company realized a net loss of  $2.1 million for the period, an improvement of 25% from the prior year period.

The company attributed the decrease in net loss to increased revenues, lower R&D and marketing expenses and partly offset by a concurrent increase of G&A expenses pursuant to merger and acquisition activity and non-cash costs relating to share based compensation.

Vringo reported that it surpassed the 400,000 download mark for its Facetones application during the period and stated that it remains committed to becoming the new leader in the fast growing mobile social arena.

Shares of VRNG have gained 77.1% in the last five days and 71.7% in the last month.

• This newsletter has been helping traders make a killing on VRNG. Click here for a 15% discount offer.
• See today’s top stock picks and market analysis
• Need fast service and cheap rates from a broker? Buy stock online at my favorite brokerage
• Want more? Check out the message board buzz for VRNG
• See what newsletters are recommending this stock pick
• Get breaking news alerts on these stocks: http://thestockmarketwatch.com/

Disclaimer:

This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. BeaconEquity.com is a wholly owned subsidiary of BlueWave Advisors, LLC. BlueWave Advisors has been compensated ten thousand dollars from the company for VRNG advertising and promotion. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision.

Related Articles

1. Small-Cap Stock on Watch: Zoom Technologies Inc. (ZOOM)
2. Biotech Stock on Watch: Arena Pharmaceuticals Inc. (ARNA)
3. Small-Cap Stock on Watch: Lee Enterprises Inc. (LEE)

Headquartered in New York City, SNAP Interactive operates as a provider of online dating applications for social networking Web sites, which has over 47 million installed users.

The company also owns an online dating Web site called AreYouInterested.com, a unique online dating site that integrates with the AreYouInterested.com iPhone & Facebook applications. Singles can have one overall experience on AreYouInterested.com across the various platforms deeply integrated with Facebook.

Shares of SNAP Interactive, along with many social media related stocks, have been drawing investors’ attention as rumors of Facebook going public began to float in the air.

SNAP Interactive was recently highlighted in a SeekingAlpha report, which suggests that it is one of the companies that could benefit from the estimated $100 billion worth IPO of Facebook. Built on the back of the Facebook platform, SNAP Interactive’s success at building and marketing Facebook platform apps and services could cause it to gain increased recognition from investors searching for additional Facebook related investment options, the report said.

SNAP Interactive last week announced it has retained strategic communications firm ICR to assist the company with its investor relations activities.  According to the company, retaining ICR marks the first step as part of an overall plan to improve communication with investors and increase its profile and visibility within the overall investment community.

STVI shares have gained 70.8% in the last five days and 215.4% in the last month.  Year-to-date, the stock is down 9.7%.

• This newsletter has been helping traders make a killing on STVI. Click here for a 15% discount offer.
• See today’s top stock picks and market analysis
• Need fast service and cheap rates from a broker? Buy stock online at my favorite brokerage
• Want more? Check out the message board buzz for STVI
• See what newsletters are recommending this stock pick
• Get breaking news alerts on these stocks: http://thestockmarketwatch.com/

Related Articles

1. Small-Cap Stock Spotlight: Tengion Inc. (TNGN)
2. Small-Cap Stock Spotlight: Cardium Therapeutics Inc. (CXM)
3. Small-Cap Stock Spotlight: A123 Systems Inc. (AONE)

Arena shares have gained 8.6% in the last five days, though the stock dropped 5.4% in the last month. Year-to-date, the stock is up 8.6%.

San Diego, Calif.-based Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs), an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

Arena’s most advanced drug candidate, lorcaserin, is intended for weight management. The company submitted a New Drug Application (NDA) for lorcaserin to the U.S. Food and Drug Administration (FDA) for regulatory approval in December 2009. The FDA then issued a complete response letter (CRL) in October 2010, outlining non-clinical and clinical reasons for its decision to not approve the drug, and provided recommendations relating to addressing the issues it raised in the CRL.  In January 2010, the Company completed an end-of-review meeting with the FDA for the locaserin NDA, which resulted in additional requirements.

On January, Arena and partner Eisai announced that the FDA has accepted, for filing and review, Arena’s resubmission of the NDA for its obesity drug. The FDA considers the resubmission a complete, class 2 response.

The company announced the submission of its response to the FDA’s CRL a week earlier, which includes data and analyses that were not incorporated in the original NDA, including the results of its Phase III BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) clinical trial, which evaluated lorcaserin for weight loss in patients with type II diabetes. The FDA target action date is set for June 27, 2012.

Also recently, Arena agreed to sell over 9.95 million shares of its common stock, at a price of $1.65775 per share, and about  9,953 shares of its Series D Convertible Preferred Stock, at a price of $1,657.75 per share, in a registered direct public offering to entities affiliated with healthcare investment organization Deerfield Management.

The Company expected to receive gross proceeds of around $33 million from the offering, $5 million of which will be used to prepay a portion of the loan principal that otherwise would have been required to be repaid in June 2013 under the existing facility agreement between Arena and Deerfield.

• This newsletter has been helping traders make a killing on ARNA. Click here for a 15% discount offer.
• See today’s top stock picks and market analysis
• Need fast service and cheap rates from a broker? Buy stock online at my favorite brokerage
• Want more? Check out the message board buzz for ARNA
• See what newsletters are recommending this stock pick
• Get breaking news alerts on these stocks: http://thestockmarketwatch.com/

Related Articles

1. Stock Alert for Arena Pharmaceuticals Inc. (ARNA)
2. Small-Cap Stock on Watch: BioSante Pharmaceuticals Inc. (BPAX)
3. Biotech Stock to Watch; VIVUS Review

JA Solar saw its shares rose 5.1% to $1.84, continuing its winning streak for the second consecutive day.  Over 8.80 million shares traded hands during the session, versus the 10-day average of 9.85 million shares.

Over the last 52 weeks, the stock has ranged from a low of $1.21 to a high of $8.57. It is currently trading above its 50-day moving average of 1.53 and below its 200-day moving average of $2.53.  Market capitalization currently stands at 302.97 million and it has 164.66 million outstanding shares

Following the stalled overhaul of the country’s clean-energy subsidy system, analysts expect a rush of solar panel installations in the coming weeks. In a phone conversation with Bloomberg, Klaus Breil, a lawmaker with the Free Democratic Party junior coalition partner, said “This delay means we’re headed toward installations of 4 gigawatts (GW) through April as subsidies are currently way too generous.”

Germany represents a major sales market of several sector bellwethers.  For Yingli Green Energy (YGE), Trina Solar (TSL) and Suntech Power (STP), the news is even more significant considering that these three manufacturers get most of their demand from the European country.  Germany installed 7.5 GW of solar power last year — topping the prior year’s record of 7.4 GW.

Solar products manufacturer JA Solar, based out of Shanghai, China, sells its products to solar manufacturers worldwide, who then assemble and integrate solar cells into modules and systems that convert sunlight into electricity for residential, commercial, and utility-scale power generation.

JASO shares have gained 4.6% in the last five days and 39.4% in the last month.  Year-to-date, the stock is down 73.9%.

• This newsletter has been helping traders make a killing on JASO. Click here for a 15% discount offer.
• See today’s top stock picks and market analysis
• Need fast service and cheap rates from a broker? Buy stock online at my favorite brokerage
• Want more? Check out the message board buzz for JASO
• See what newsletters are recommending this stock pick
• Get breaking news alerts on these stocks: http://thestockmarketwatch.com/

Related Articles

1. Stock Alert for JA Solar Holdings Co. Ltd. (JASO)
2. Stock Alert for JA Solar Holdings Co. Ltd. (JASO)
3. Renewable Energy Trade Option: Energy Conversion Devices Review

Over the last 52 weeks, the stock has ranged from a low of $0.25 to a high of $6.30. It is currently trading above its 50-day and 200-day moving averages of $1.08 and $0.74, respectively.  Market capitalization currently stands at 92.77 million and it has 85.11 million outstanding shares.

Pacific Ethanol, based out of Sacramento, California, markets and produces  low-carbon renewable fuels in the Western United States. It also sells co-products, including wet distillers grain (WDG), a nutritional animal feed.  The company generated net sales of $328.3 million for 2010, as compared with $316.6 million for 2009. Total gallons sold were 271.6 million in 2010, an increase of 98.9 million gallons over the 172.7 million gallons sold in the prior year.

Serving integrated oil companies and gasoline marketers who blend ethanol into gasoline, Pacific Ethanol provides transportation, storage and delivery of ethanol through third-party service providers in the Western United States, primarily in California, Nevada, Arizona, Oregon, Colorado, Idaho and Washington.

Investors last month welcomed the news that the company closed its $4.6 million purchase of an additional 7% ownership interest in New PE Holdco LLC, increasing its total ownership interest to 34%. New PE Holdco LLC owns, and the company operates, the four Pacific Ethanol production facilities.

The company also announced the closing of an $8.0 million private placement of nearly 7.63 million shares of common stock and warrants to purchase up to approximately 4.96 million shares of common stock.

PEIX have slipped 5.2% in the last five days, though the stock gained 28.8% in the last month.  Year-to-date, the stock is down 81.7%.

• This newsletter has been helping traders make a killing on PEIX. Click here for a 15% discount offer.
• See today’s top stock picks and market analysis
• Need fast service and cheap rates from a broker? Buy stock online at my favorite brokerage
• Want more? Check out the message board buzz for PEIX
• See what newsletters are recommending this stock pick
• Get breaking news alerts on these stocks: http://thestockmarketwatch.com/

Related Articles

1. Stock Alert for Pacific Ethanol Inc. (PEIX)
2. Stock Alert for Pacific Ethanol Inc. (PEIX)
3. Alternative Energy Trade Option: Energy Conversion Devices Inc. (ENER) Review

Complete Genomics Inc. (GNOM) is a life sciences company that has developed and commercialized an innovative DNA sequencing platform that it believes will become the preferred solution for complete human genome sequencing and analysis. The Complete Genomics Analysis Platform, or CGA™ Platform, combines the Company’s proprietary human genome sequencing technology with its advanced informatics and data management software.  GNOM offers this solution as an innovative, end-to-end, outsourced service and provide customers with data that is immediately ready to be used for genome-based research. Its CGA™ Service solution provides academic and biopharmaceutical researchers with complete human genomic data and analysis at an unprecedented quality, cost and scale. GNOM generated revenue of $9.4 million for fiscal 2010, which compares to revenue of $0.6 million in fiscal 2009.

Source: Reuters.com, SEC Filings.

Investment Highlights

Shares of Complete Genomics Inc. (GNOM) advanced as much as 32% to $3.30 in Wednesday’s trading, stretching gains for the third straight trading session.  Over 3.66 million shares exchanged hands during the day, versus the 10-day average of over 777 K. The stock has a 52-week range of $0.82 – $6.38. It is currently trading above  its 50-day moving average of $2.92 and below its 200-day moving average of $6.47.

Shares of GNOM have gained 18.7% in the last five days and 4.9% in the last month.  Year-to-date, the stock is down 82.2%.

GNOM last week announced that the Journal of Computational Biology, a peer-reviewed scientific journal dedicated to computational biology and bioinformatics, has recently published online the Company’s paper describing some of the computational methods that enable it to produce highly-accurate whole human genome sequencing data.

Mountain View, CA-based GNOM performs whole human genome sequencing using proprietary biochemistry based on DNA nanoball arrays and combinatorial probe-anchor ligation sequencing. As these methods produce reads with unique characteristics, the Company has developed new methods that call single nucleotide polymorphisms (SNPs), short substitutions and insertions/deletions, GNOM said in statement.

The paper can be viewed at http://www.liebertonline.com/doi/full/10.1089/cmb.2011.0201

“The methods described in this paper produce very accurate variant calls,” commented Dr. Clifford Reid, chairman, president and CEO of GNOM. “The algorithms described in this paper have been used for all of our 69 genome public data repository and the more than 3,800 complete, deeply sequenced human genomes we have delivered to customers to date.”

GNOM’s genome data repository can be accessed for free at http://www.completegenomics.com/sequence-data/download-data/

GNOM shareholders earlier this month welcomed the news that the company delivered about 3,000 genomes to its customers in 2011 and is entering the new year with contracts for about 5,800 genomes.

During the last three months of last year, GNON delivered more than 600 genomes to its customers, trailing its projection of 900 genomes.  According to the Company, nearly 300 genomes took longer to move through the pipeline than anticipated and will ship in the first quarter of 2012.

GNOM last year secured orders for about 8,000 genomes worth approximately $39 million.

Source: http://www.completegenomics.com/news-events/press-releases/

Financial Summary

GNOM reported revenue of $4.2 million for the quarter ended September 30, 2011, unchanged from revenue reported in the third quarter of the prior year.  The Company recognized revenue for over 700 genomes compared to over 300 genomes recognized in the third quarter of 2010.

Costs and operating expenses were $25.0 million compared to $14.9 million in the third quarter of 2010.

GNOM realized a net loss of $21.6 million for the quarter.  That compared to a net loss of $20.5 million in the comparable quarter of the prior year, which included an $8.8 million non-cash expense resulting from the accounting adjustment to market value of certain equity securities.

The Company’s backlog as of September 30, 2011, was approximately $24 million and 4,800 genomes. It ended the third quarter of 2011 with $105.1 million in cash, cash equivalents and short-term investments.

Source: http://www.completegenomics.com/news-events/press-releases/Complete-Genomics-Reports-Results-for-Third-Quarter-2011-133456158.html

Technical Analysis

Source: http://stockcharts.com

GNOM is within its Bollinger Bands. This is a normal condition suggesting that it is neither overbought nor oversold relative to the recent levels.

The MACD for GNOM currently indicates a strong bearish signal for two reasons. First, the MACD is below the signal line, a 9-day moving average. Second, the MACD is below the critical level of 0, which implies that the underlying moving averages are trending lower.

Comparative Analysis

Source: Thomson Financial

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

Related Articles

1. Renewable Energy Trade Option: Energy Conversion Devices Review
2. Alternative Energy Trade Option: Energy Conversion Devices Inc. (ENER) Review
3. Small-Cap Stock Spotlight: LiveDeal Inc. (LIVE) Trades Higher after CEO Sacking